Literature DB >> 33505807

Differential relieving effects of shikonin and its derivatives on inflammation and mucosal barrier damage caused by ulcerative colitis.

Hongwei Han1,2, Wenxue Sun1,2, Lu Feng1,2, Zhongling Wen1,2, Minkai Yang1,2, Yingying Ma1,2, Jiangyan Fu1,2, Xiaopeng Ma1,2, Xinhong Xu1,2, Zhaoyue Wang1,2, Tongming Yin2, Xiao-Ming Wang1,2, Gui-Hua Lu1,3, Jin-Liang Qi1,2, Hongyan Lin1,2, Yonghua Yang1,2.   

Abstract

BACKGROUND: Ulcerative colitis (UC) is one of the most challenging human diseases. Natural shikonin (SK) and its derivatives (with have higher accumulation) isolated from the root of Lithospermum erythrorhizon have numerous beneficial effects, such as wound healing and anti-inflammatory activities. Some researchers have reported that hydroxynaphthoquinone mixture (HM) and SK attenuate the acute UC induced by dextran sulfate sodium (DSS). However, no existing study has systemically investigated the effectiveness of SK and other hydroxynaphthoquinone natural derivative monomers on UC.
METHODS: In this study, mice were treated with SK and its derivatives (25 mg/kg) and mesalazine (200 mg/kg) after DSS administration daily for one week. Disease progression was monitored daily by observing the changes in clinical signs and body weight.
RESULTS: Intragastric administration natural single naphthoquinone attenuated the malignant symptoms induced by DSS. SK or its derivatives remarkably suppressed the serum levels of pro-inflammatory cytokines while increasing the inflammatory cytokine interleukin (IL)-10 . Additionally, both SK and alkanin restrained the activities of cyclooxygenase-2 (COX-2), myeloperoxidase (MPO) and inducible nitric oxide synthase (iNOS) in serum and colonic tissues. SK and its derivatives inhibited the activation of nucleotide binding oligomerization domain-like receptors (NLRP3) inflammasome and NF-κB signaling pathway, thereby relieving the DSS-induced disruption of epithelial tight junction (TJ) in colonic tissues.
CONCLUSIONS: Our findings shed more lights on the pharmacological efficacy of SK and its derivatives in UC against inflammation and mucosal barrier damage. ©2021 Han et al.

Entities:  

Keywords:  Anti-inflammatory; Epithelial tight junction; Hydroxynaphthoquinone; Shikonin and its derivatives; Ulcerative colitis

Year:  2021        PMID: 33505807      PMCID: PMC7797173          DOI: 10.7717/peerj.10675

Source DB:  PubMed          Journal:  PeerJ        ISSN: 2167-8359            Impact factor:   2.984


  29 in total

Review 1.  Pharmacological properties of shikonin - a review of literature since 2002.

Authors:  Isabel Andújar; José Luis Ríos; Rosa María Giner; María Carmen Recio
Journal:  Planta Med       Date:  2013-10-23       Impact factor: 3.352

Review 2.  The Role of Myeloperoxidase in Biomolecule Modification, Chronic Inflammation, and Disease.

Authors:  Michael J Davies; Clare L Hawkins
Journal:  Antioxid Redox Signal       Date:  2020-03-06       Impact factor: 8.401

3.  Shikonin inhibits the lipopolysaccharide-induced release of HMGB1 in RAW264.7 cells via IFN and NF-κB signaling pathways.

Authors:  Ying Yang; Jing Wang; Qiao Yang; Shanshan Wu; Zhenggang Yang; Haihong Zhu; Min Zheng; Weixia Liu; Wei Wu; Jiliang He; Zhi Chen
Journal:  Int Immunopharmacol       Date:  2014-01-19       Impact factor: 4.932

4.  Shikonin changes the lipopolysaccharide-induced expression of inflammation-related genes in macrophages.

Authors:  Lucia Satiko Yoshida; Tomohito Kakegawa; Yasukatsu Yuda; Hiromi Takano-Ohmuro
Journal:  J Nat Med       Date:  2017-07-11       Impact factor: 2.343

Review 5.  Inflammation and colon cancer.

Authors:  Janos Terzić; Sergei Grivennikov; Eliad Karin; Michael Karin
Journal:  Gastroenterology       Date:  2010-06       Impact factor: 22.682

6.  Real-world evidence on adherence, persistence, switching and dose escalation with biologics in adult inflammatory bowel disease in the United States: A systematic review.

Authors:  Shahnaz Khan; Ewa Rupniewska; Mackenzie Neighbors; David Singer; Joseph Chiarappa; Camilo Obando
Journal:  J Clin Pharm Ther       Date:  2019-03-14       Impact factor: 2.512

7.  Biological activity of some naturally occurring resins, gums and pigments against in vitro LDL oxidation.

Authors:  Nikolaos K Andrikopoulos; Andriana C Kaliora; Andreana N Assimopoulou; Vassilios P Papapeorgiou
Journal:  Phytother Res       Date:  2003-05       Impact factor: 5.878

8.  Inflammatory bowel diseases, 5-aminosalicylic acid and sulfasalazine treatment and risk of acute pancreatitis: a population-based case-control study.

Authors:  Estrid Muff Munk; Lars Pedersen; Andrea Floyd; Bente Nørgård; Henrik Højgaard Rasmussen; Henrik T Sørensen
Journal:  Am J Gastroenterol       Date:  2004-05       Impact factor: 10.864

9.  Crohn's disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: a real life cohort study.

Authors:  Christopher Ma; Vivian Huang; Darryl K Fedorak; Karen I Kroeker; Levinus A Dieleman; Brendan P Halloran; Richard N Fedorak
Journal:  J Crohns Colitis       Date:  2014-06-16       Impact factor: 9.071

10.  Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry.

Authors:  Gary R Lichtenstein; Brian G Feagan; Russell D Cohen; Bruce A Salzberg; Robert H Diamond; Samiyeh Price; Wayne Langholff; Anil Londhe; William J Sandborn
Journal:  Am J Gastroenterol       Date:  2012-08-14       Impact factor: 10.864

View more
  4 in total

1.  Combined Shikonin-Loaded MPEG-PCL Micelles Inhibits Effective Transition of Endothelial-to-Mesenchymal Cells.

Authors:  Guanglin Li; Chenxu Shang; Qingqing Li; Lifang Chen; Zejun Yue; Lingxuan Ren; Jianjun Yang; Jiye Zhang; Weirong Wang
Journal:  Int J Nanomedicine       Date:  2022-09-24

Review 2.  Review of Shikonin and Derivatives: Isolation, Chemistry, Biosynthesis, Pharmacology and Toxicology.

Authors:  Snehlata Yadav; Ajay Sharma; Gulzar Ahmad Nayik; Raymond Cooper; Garima Bhardwaj; Harvinder Singh Sohal; Vishal Mutreja; Ramandeep Kaur; Franklin Ore Areche; Mohannad AlOudat; Ayaz Mukarram Shaikh; Béla Kovács; Abdelhakam Esmaeil Mohamed Ahmed
Journal:  Front Pharmacol       Date:  2022-07-01       Impact factor: 5.988

3.  Shikonin ameliorated mice colitis by inhibiting dimerization and tetramerization of PKM2 in macrophages.

Authors:  Baoyuan Huang; Qiumei Wang; Lin Jiang; Shuru Lu; Chengcheng Li; Chunqi Xu; Caiyan Wang; Enxin Zhang; Xiaojun Zhang
Journal:  Front Pharmacol       Date:  2022-08-17       Impact factor: 5.988

Review 4.  Research Progress on Structure and Anti-Gynecological Malignant Tumor of Shikonin.

Authors:  Li-Na Ke; Ling-Qi Kong; Huan-Huan Xu; Qin-Hua Chen; Yun Dong; Bin Li; Xiao-Hua Zeng; Hong-Mei Wang
Journal:  Front Chem       Date:  2022-07-08       Impact factor: 5.545

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.